Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update
The New York Stock Exchange, a subsidiary of Intercontinental Exchange, issued its daily pre-market floor advisory, headlined by Moonwalk Biosciences' $70 million Series B to advance RNAi development, with CEO Dr. Alex Aravanis set to appear on NYSE Live. The roundup also covered defense startup Covenant opening a 105,000 square-foot Texas factory and introducing Anthem, a heavy-payload long-range weapon system, backed by more than $250 million raised across three rounds from Andreesen Horowitz and Lightspeed. Macro color included ICE Brent Crude topping $100 a barrel for the first time since July amid the Middle East conflict, ahead of inflation readings due later this week.
Key figures
- Moonwalk series b
- $70 million
- Covenant total funding
- more than $250 million across three rounds
- Brent crude usd per barrel
- 100
- Covenant factory square feet
- 105000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.